Moderna, INC Form 4 insider transactions

Moderna's Chief Legal Officer, Shannon Klinger, engaged in stock transactions involving the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Moderna's President, Stephen Hoge, executed stock transactions involving the vesting of restricted stock units and a sale to cover tax obligations.

Moderna's Chief Financial Officer, James Mock, engaged in multiple stock transactions, including the vesting of performance and restricted stock units and a sale to cover tax obligations, as detailed in a recent SEC filing.

Moderna's Chief Legal Officer, Shannon Klinger, engaged in stock transactions involving the vesting of restricted stock units and subsequent sales to cover tax obligations.

Moderna's President, Stephen Hoge, executed stock transactions involving the vesting of restricted stock units and sales to cover tax obligations.

Moderna's President, Stephen Hoge, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Director Abbas Hussain acquired stock options and restricted stock units in Moderna, Inc. on October 2, 2024.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions related to restricted stock units.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Moderna's President, Stephen Hoge, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Moderna's President, Stephen Hoge, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Moderna's Chief Financial Officer, James Mock, recently engaged in transactions involving the vesting of performance and restricted stock units, followed by a sale of shares to cover tax obligations.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax withholding obligations.

Moderna's President, Stephen Hoge, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director David M. Rubenstein reports acquisition of Moderna stock options and restricted stock units, set to vest in the coming years.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at a price of $121.12 per share on July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on July 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Financial Officer of Moderna, James Mock, reports acquisition and disposal of common stock and restricted stock units.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 18, 2024, under a pre-arranged trading plan.

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at $138.16 per share on June 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Moderna CEO Stephane Bancel received 26,840 shares of common stock through a pro rata distribution from Flagship Ventures Fund IV, while also reporting indirect ownership of shares held by Boston Biotech Ventures, LLC and OCHA LLC.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold a significant number of shares indirectly held through Flagship Ventures funds and Flagship Pioneering.